Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease

Neuroscience Letters

Volumn 436, Issue 2, 2008, Pages 196-200

  Kim, Tae Suk ^a   Lim, Hyun Kook ^a   Lee, Ji Youl ^a   Kim, Dai Jin ^a   Park, Sanghi ^b   Lee, Chul ^a   Lee, Chang Uk ^a  

^a The Catholic University of Korea   (South Korea)

^b Holy Family Hospital   (South Korea)

Author keywords

Alzheimer's disease; Chemokine; Fractalkine; Mild cognitive impairment; Pathogenesis

Indexed keywords

FRACTALKINE;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PATHOGENESIS; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; CHEMOKINE CX3CL1; CHI-SQUARE DISTRIBUTION; COGNITION DISORDERS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MENTAL STATUS SCHEDULE;

EID: 41949125406     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.03.019     Document Type: Article

References (32)

1. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorder, 4th ed., American Psychiatric Association, Washington, DC, 1994.
2. Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., Greaves D.R., Zlotnik A., and Schall T.J. A new class of membrane-bound chemokine with a CX3C motif. Nature 385 (1997) 640-644
3. D'Andrea M.R., Cole G.M., and Ard M.D. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol. Aging 25 (2004) 675-683
4. Duan R.S., Yang X., Chen Z.G., Lu M.O., Morris C., Winblad B., and Zhu J. Decreased fractalkine and increased IP-10 expression in aged brain of APP(swe) transgenic mice. Neurochem. Res. 33 (2008) 1085-1089
5. Galimberti D., Fenoglio C., Lovati C., Venturelli E., Guidi I., Corra B., Scalabrini D., Clerici F., Mariani C., Bresolin N., and Scarpini E. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol. Aging 27 (2006) 1763-1768
6. Harrison J., Jiang Y., Chen S., Xia Y., Maciejewski D., McNamara R., Streit W., Salafranca M., Adhikari S., Thompson D., Botti P., Bacon P., and Feng L. Role for neuronally derived fractalkine in mediating unique interactions between neurons and CX3CR1-expressing microglia. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 10896-10901
7. Hatori K., Nagai A., Heisel R., Ryu J.K., and Kim S.U. Fractalkine and fractalkine receptors in human neuron and glial cells. J. Neurosci. Res. 69 (2002) 418-426
8. Heneka M.T., and O'Banion M.K. Inflammatory processes in Alzheimer's disease. J. Neuroimmunol. 184 (2007) 69-91
9. Ikeda S., Saito H., Fukatsu K., Inoue T., Han I., Furukawa S., Matsuda T., and Hidemura A. Dietary restriction impairs neutrophil exudation by reducing CD11b/CD18 expression and chemokine production. Arch. Surg. 136 (2001) 297-304
10. Imai T., Hieshima K., Haskell C., Baba M., Nagira M., Nishimura M., Kakizaki M., Takagi S., Nomiyama H., Schall T.J., and Yoshie O. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91 (1997) 521-530
11. Ishizuka K., Kimura T., Igata R., Katsragi S., Takamatsu J., and Miyarawa T. Identification of monocyte chemoattractant protein-1 on senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin. Neurosci. 51 (1997) 135-138
12. Kastenbauer S., Koedel U., Wick M., Kieseier B.C., Hartung H.P., and Pfister H.W. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. J. Neuroimmunol. 137 (2003) 210-217
13. McGeer E., and McGeer P.L. Inflammatory processes in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 741-749
14. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
15. Meda L., Bernasconi S., Bonaiuto C., Sozzani S., Zhou D., Otvos A., Mantivani F., Rossi M.A., and Cassatella. Beta-amyloid (25-35) peptide and IFN-gamma synergistically induce the production of the chemotactic cytokine MCP-1/JE in monocytes, and microglial cells. J. Immunol. 157 (1996) 1213-1218
16. Morris J.C., Storandt M., Miller J.P., McKeel D.W., Price J.L., Rubin E.H., and Berg L. Mild cognitive impairment represents early-stage Alzheimer disease. Arch. Neurol. 58 (2001) 397-405
17. Pan Y., Lloyd C., Zhou H., Dolich S., Deeds J., Gonzalo J.A., Vath J., Gosselin M., Ma J., Dussault B., Woolf E., Alperin G., Culpepper J., Gutierrez-Ramos J.C., and Gearing D. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 387 (1997) 611-617
18. Park J.H., and Kwon Y.C. Modification of the Mini Mental State Examination for use in the elderly in a non-western society: 1. Development of Korean version Mini Mental State Examination. Int. J. Geriatr. Psychiatry 5 (1990) 381-387
19. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256 (2004) 183-194
20. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., and Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56 (1999) 303-308
21. Rollins B. Chemokines. Blood 90 (1997) 909-928
22. Rosen W.G., Terry R.D., Fuld P.A., Katzman R., and Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann. Neurol. 7 (1980) 486-488
23. Schwaeble W.J., Stover C.M., Schall T.J., Dairaghi D.J., Trinder P.K., Linington C., Iglesias A., Schubart A., Lynch N.J., Weihe E., and Schafer M.K. Neuronal expression of fractalkine in the presence and absence of inflammation. FEBS Lett. 439 (1998) 203-207
24. Sporer B., Kastenbauer S., Koedel U., Arendt G., and Pfister H.W. Increased intrathecal release of soluble fractalkine in HIV-infected patients. AIDS Res. Hum. Retroviruses 19 (2003) 111-116
25. Streit W.J., Conde J.R., and Harrison J.K. Chemokines and Alzheimer's disease. Neurobiol. Aging 22 (2001) 909-913
26. Tarkowski E., Andreasen N., Tarkowski A., and Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 74 (2003) 1200-1205
27. Tong N., Perry S.W., Zhang Q., James H.J., Guo H., Brooks A., Bal H., Kinnear S.A., Fine S., Epstein L.G., Dairaghi D., Schall T.J., Gendelman H.E., Dewhurst S., Sharer L.R., and Gelbard H.A. Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the central nervous system. J. Immunol. 164 (2000) 1333-1339
28. Tsou C.L., Haskell C.A., and Charo I.F. Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J. Biol. Chem. 276 (2001) 44622-44626
29. Tuppo E.E., and Arias H.R. The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell Biol. 37 (2005) 289-305
30. Xia M.Q., Qin S.X., Wu L.J., Mackay C.R., and Hyman B.T. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brain. Am. J. Pathol. 153 (1998) 31-37
31. Yoneda O., Imai T., Goda S., Inoue H., Yamauchi A., Okazaki T., Imai H., Yoshie O., Bloom E.T., Domae N., and Umehara H. Fractalkine-mediated endothelial cell injury by NK cells. J. Immunol. 164 (2000) 4055-4062
32. Zujovic V., Benavides J., Vige X., Varter C., and Taupin V. Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia 29 (2000) 305-315